World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
34308
World Ranking
16414
National Ranking
517

Narikazu Boku publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Narikazu Boku sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 769 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Narikazu Boku D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Narikazu Boku sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Narikazu Boku is affiliated with St. Marianna University School of Medicine in Japan and has a research focus primarily within the field of Medicine. Their work spans multiple subfields, including Pulmonary and Respiratory Medicine, Oncology, Surgery, Gastroenterology, and Epidemiology.

The scientist's research covers several major topics such as:

  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Gastrointestinal Tumor Research and Treatment
  • Metastasis and carcinoma case studies
  • Cancer Immunotherapy and Biomarkers
  • Esophageal Cancer Research and Treatment
  • Cancer Treatment and Pharmacology

Narikazu Boku has published extensively in leading oncology and medical journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Gastric Cancer
  • Annals of Oncology
  • International Journal of Clinical Oncology
  • Research Square

Collaborations are also a notable aspect of their academic work. Prominent frequent co-authors include:

  • Masanori Terashima
  • Takaki Yoshikawa
  • Atsuo Takashima
  • Hirokazu Shoji
  • Ken Kato

Among the recent papers authored or co-authored by Narikazu Boku are:

  • "Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial", 2022, The Lancet Oncology
  • "Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100", 2020, Journal of Clinical Oncology
  • "Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)", 2020, Journal of Clinical Oncology
  • "Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial", 2020, Gastric Cancer
  • "LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study", 2020, Annals of Oncology

Best Publications

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

    Katsuhiko Uesaka;Narikazu Boku;Akira Fukutomi;Yukiyasu Okamura

  • Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

    Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa

  • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

    Narikazu Boku;Seiichiro Yamamoto;Haruhiko Fukuda;Kuniaki Shirao

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)

    Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao;Narikazu Boku

  • Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

    Shuichi Hironaka;Shinya Ueda;Hirofumi Yasui;Tomohiro Nishina

  • New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife.

    M. Ohkuwa;K. Hosokawa;N. Boku;A. Ohtu

  • Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

    Yung Jue Bang;E. Yañez Ruiz;E. Van Cutsem;K. W. Lee

  • Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus

    Atsushi Ohtsu;Narikazu Boku;Kei Muro;Keisho Chin

  • Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus

    Satoshi Ishikura;Keiji Nihei;Atsushi Ohtsu;Narikazu Boku

  • Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer

    Narikazu Boku;Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao

  • HER2-positive gastric cancer.

    Narikazu Boku

  • Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions

    Chikatoshi Katada;Manabu Muto;Tetsuro Manabe;Narikazu Boku

  • Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

    Ken Kato;Kei Muro;Keiko Minashi;Atsushi Ohtsu

  • Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

    W Koizumi;S Tanabe;K Saigenji;A Ohtsu

  • A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms

    Shin'ichi Miyamoto;Manabu Muto;Yasuo Hamamoto;Narikazu Boku

  • Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

    Yung Jue Bang;Rui Hua Xu;Keisho Chin;Keun Wook Lee

  • Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

    Tomonori Yano;Toshihiko Doi;Atsushi Ohtsu;Narikazu Boku

Frequent Co-Authors

Atsushi Ohtsu
Atsushi Ohtsu Juntendo University
Kei Muro
Kei Muro National Cancer Research Institute, UK
Mitsuru Sasako
Mitsuru Sasako Hyogo College of Medicine
Satoshi Morita
Satoshi Morita Kyoto University
Takuji Okusaka
Takuji Okusaka National Cancer Centre
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Junji Furuse
Junji Furuse Kyorin University
Toshihiko Doi
Toshihiko Doi Okayama University
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Kazuto Nishio
Kazuto Nishio Kindai University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a wide range of healthcare careers. For students seeking alternative options online, there are several flexible pathways to consider. For example, direct entry msn programs for non-nurses online allow individuals with non-nursing backgrounds to earn a master's degree in nursing and enter the field faster.

If you're looking to become a registered nurse, some schools are renowned for being accessible. Researching the easiest rn program to get into can help you identify institutions with higher acceptance rates or fewer admission barriers.

For those interested in health administration rather than patient care, online medical coding classes with financial aid offer a cost-effective way to start a career in medical billing and coding.

There are also nursing programs that simplify admission requirements. For example, you can find an lpn program without teas test, helping you quickly start a practical nursing career without additional standardized exams.

These alternative pathways make it easier than ever for students from diverse backgrounds to enter the growing healthcare field.

Best Scientists Citing Narikazu Boku

Trending Scientists

Recently Published Articles